Stay updated on Safety and Efficacy of Ibrutinib and Pembrolizumab in CLL/MCL Clinical Trial
Sign up to get notified when there's something new on the Safety and Efficacy of Ibrutinib and Pembrolizumab in CLL/MCL Clinical Trial page.

Latest updates to the Safety and Efficacy of Ibrutinib and Pembrolizumab in CLL/MCL Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedThe page now shows a new site revision tag (v3.6.5) replacing the previous revision tag (v3.6.4), indicating a minor backend/UI update.SummaryDifference0.1%

- Check23 days agoNo Change Detected
- Check30 days agoChange DetectedA new revision label, Revision: v3.6.4, was added and the previous label, Revision: v3.6.3, was removed, indicating an update to the page's revision history.SummaryDifference0.1%

- Check52 days agoChange DetectedUpdate to revision label on the page from v3.6.2 to v3.6.3, indicating a new page version. This update likely includes minor behind-the-scenes changes without altering the displayed study details.SummaryDifference0.1%

- Check59 days agoChange DetectedThe page footer now shows Revision: v3.6.2, replacing the previous Revision: v3.6.0.SummaryDifference0.1%

- Check73 days agoChange DetectedRecruitment status now indicates no further participant recruitment; new help sections were added to assist users in reading, understanding, and joining studies, along with minor label formatting changes and a revision tag.SummaryDifference0.5%

- Check80 days agoChange DetectedThe page's revision tag was updated to v3.5.5, replacing v3.5.4. This represents a small internal update to the page's revision history and does not change the displayed study information.SummaryDifference0.1%

Stay in the know with updates to Safety and Efficacy of Ibrutinib and Pembrolizumab in CLL/MCL Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety and Efficacy of Ibrutinib and Pembrolizumab in CLL/MCL Clinical Trial page.